The Merck & Co., Inc. line shows up 168 times in the congressional disclosure record between 2013 and 2026, filed by 48 members: 88 purchases against 80 sales. On balance the chamber has been net buyers, and the purchases sit up 53.9% against the latest close.
*Purchases only, weighted by the midpoint of each disclosed dollar band and marked to the latest close. Filings report a range, never a share count, so this follows the stock rather than anyone's position size.
Reported a MRK purchase in filings from the last 90 days, newest first. 1 member.
Members ranked by how their reported MRK purchases have moved since, over roughly the last three years, weighted by disclosed band midpoint and marked to the latest close.
| Date | Member | Type | Amount | Est. price | Latest close | Return |
|---|---|---|---|---|---|---|
| 2016-01-14 | Sheldon Whitehouse | BUY | $1K–$15K | $49.43 | $140.61 2026-10-26 | +184.5% |
| 2015-11-18 | Katherine M. Clark | SELL | $15K–$50K | $51.75 | $140.61 2026-10-26 | -171.7% exit |
| 2015-08-12 | James M Inhofe | BUY | $15K–$50K | $55.59 | $140.61 2026-10-26 | +152.9% |
| 2015-07-10 | Sheldon Whitehouse | BUY | $1K–$15K | $55.30 | $140.61 2026-10-26 | +154.3% |
| 2015-07-09 | James M Inhofe | BUY | $50K–$100K | $54.75 | $140.61 2026-10-26 | +156.8% |
| 2015-05-28 | E. Scott Rigell | BUY | $1K–$15K | $56.97 | $140.61 2026-10-26 | +146.8% |
| 2015-05-27 | Sheldon Whitehouse | BUY | $1K–$15K | $56.74 | $140.61 2026-10-26 | +147.8% |
| 2015-05-27 | Sheldon Whitehouse | BUY | $1K–$15K | $56.74 | $140.61 2026-10-26 | +147.8% |
| 2015-04-06 | Michael T. McCaul | SELL | $100K–$250K | $54.56 | $140.61 2026-10-26 | -157.7% exit |
| 2015-04-06 | Michael T. McCaul | SELL | $100K–$250K | $54.56 | $140.61 2026-10-26 | -157.7% exit |
| 2015-03-31 | James B. Renacci | BUY | $1K–$15K | $54.85 | $140.61 2026-10-26 | +156.4% |
| 2015-03-25 | Michael T. McCaul | SELL | $50K–$100K | $55.59 | $140.61 2026-10-26 | -152.9% exit |
| 2015-03-25 | Michael T. McCaul | SELL | $15K–$50K | $55.59 | $140.61 2026-10-26 | -152.9% exit |
| 2015-02-16 | Dan Benishek | BUY | $1K–$15K | $56.12 | $140.61 2026-10-26 | +150.6% |
| 2015-01-20 | John A. Yarmuth | BUY | $1K–$15K | $59.74 | $140.61 2026-10-26 | +135.4% |
| 2013-05-22 | SUSAN M COLLINS | SELL | $1K–$15K | $44.57 | $140.61 2026-10-26 | -215.5% exit |
| 2013-03-04 | THAD COCHRAN | BUY | $1K–$15K | $41.35 | $140.61 2026-10-26 | +240.0% |
| Kenny Marchant | BUY | $1K–$15K | — | — | — |
Buys are marked to the latest close and treated as open. A sell tagged rt closes an earlier disclosed buy in the same name. exit shows how the stock moved after the member sold.
48 members of the U.S. House and Senate have disclosed Merck & Co., Inc. transactions under the STOCK Act — 88 purchases and 80 sales. The full member-by-member breakdown, with dates and dollar ranges, is in the table above.
1 member disclosed a MRK purchase in the last 90 days — most recently Maria Elvira Salazar on 2026-08-19. See the "Lawmakers who bought MRK recently" section above for the dated list.
Notional-weighted, lawmakers' disclosed MRK buys are up 53.9% versus the latest close of $150.33. Each trade's own return — and realized round-trips on matched sells — is in the Return column.
Yes. Under the 2012 STOCK Act, members of Congress may buy and sell individual stocks but must publicly disclose each transaction within 45 days. Bargo surfaces those filings so you can see who traded MRK and how it performed.